Rexgenero receives confirmation from EMA / CAT that REX-001 meets the definition of an ATMP

24/07/2015

London UK. Rexgenero receives notification from The Committee for Advanced Therapies (CAT) of the European Medicines Agency (EMA) that EMA / CAT considers REX-001 to be a tissue engineered product on the basis that cells are not intended to be used for the same essential function and restore physiological functions (regenerating, repairing and replacing human tissue) by exerting pharmacological, immunological and metabolic actions and therefore is an Advanced Therapy Medicinal Product (ATMP) as provided in Article 2(1) of Regulation (EC) No 1394/2007.

Ixaka Appoints Karen Miller as Chief Scientific Officer

12/07/2022

London, UK, 12 July 2022: Ixaka Ltd, an integrated cell and gene therapy company focused on boosting the natural power…

Ixaka and Minaris Regenerative Medicine Sign Tech Transfer and GMP Manufacturing Agreement for Lead Cell Therapy Candidate REX-001

27/06/2022

REX-001 is an autologous multi-cell therapy (MCT) in development for the treatment of chronic limb-threatening ischemia (CLTI) in patients with…

Ixaka expands IP portfolio to enable use of targeted nanoparticle in vivo gene delivery technology with any cargo in any therapeutic area

21/03/2022

London, UK, 21 March 2022– Ixaka Ltd, an integrated cell and gene therapy company, today announces an expansion of its…